ASAM
Medetomidine withdrawal can turn critical fast: ASAM outlines how to respond

Clinical takeaway: Suspect medetomidine involvement when opioid-associated overdose causes persistent sedation and bradycardia, or withdrawal rapidly produces severe hypertension, tachycardia, and vomiting. Restore breathing with naloxone when indicated, and promptly treat suspected medetomidine withdrawal with alpha-2 agonists and monitoring appropriate to severity.
The American Society of Addiction Medicine has released its first clinical considerations for medetomidine intoxication and withdrawal, addressing an emerging veterinary sedative in the unregulated opioid supply. The recommendations rely largely on expert consensus and observational data, with research still too limited to support a formal clinical practice guideline.
“The course of withdrawal is often unpredictable and can quickly escalate from mild to severe,” said guidance coauthor Jeanmarie Perrone, MD, FASAM, in ASAM’s announcement.
Intoxication typically causes sedation and bradycardia, whereas withdrawal can begin within hours and progress to autonomic instability, encephalopathy, and end-organ injury. Routine toxicology screens do not detect medetomidine, making clinical recognition and awareness of local drug-supply surveillance essential.
Key Recommendations
- Target breathing with naloxone. Administer incremental doses until adequate respiration returns; persistent sedation alone should not trigger further dosing because naloxone does not reverse medetomidine’s effects. Provide supportive care, and avoid veterinary alpha-2 antagonists, which are not recommended for humans.
- Start alpha-2 agonists early. Oral clonidine is first-line therapy; guanfacine or tizanidine may provide additional control. Severe withdrawal may require substantially higher doses than usual, with frequent reassessment of blood pressure, heart rate, and overall clinical status.
- Escalate refractory withdrawal. Use IV dexmedetomidine when vomiting persists despite antiemetics and alpha-2 agonists, or severe tachycardia, hypertension, agitation, and encephalopathy emerge despite treatment. Hospitalization, telemetry, and potentially ICU care may be necessary.
- Address vomiting promptly. IV or IM dopamine D2 antagonists, such as droperidol, haloperidol, olanzapine, or prochlorperazine, can facilitate oral treatment when ondansetron is ineffective. Monitor for QTc prolongation and extrapyramidal effects.
- Treat concurrent opioid withdrawal and OUD. If buprenorphine is selected, use low-dose initiation with full opioid agonist overlap: medetomidine withdrawal can inflate Clinical Opiate Withdrawal Scale scores and increase the risk of premature standard-dose initiation. Methadone can generally follow standard initiation protocols with appropriate QTc assessment.
- Taper gradually and arrange follow-up. Reduce high-dose alpha-2 agonists as symptoms stabilize; continued therapy with tapering over weeks to months may be needed after discharge. Close monitoring helps identify hypotension or rebound withdrawal.
Source: American Society of Addiction Medicine. (2026 Nov 10). ASAM Clinical Considerations: Medetomidine Intoxication and Withdrawal